Drugs that Impair Safe Driving; Request for Comments, 33305-33306 [2018-15209]

Download as PDF daltland on DSKBBV9HB2PROD with NOTICES Federal Register / Vol. 83, No. 137 / Tuesday, July 17, 2018 / Notices inventory of interlock programs to support program management by documenting lessons learned and identifying solutions to common problems. The collected information would be from publicly available sources such as program websites, and from program administrators and staff. Administrators would be invited to take a 15-minute online self-administered questionnaire, and administrators and staff would be invited to participate in a semi-structured interview over the telephone, up to one hour (with one interview per program). Respondents: Respondents will be administrators and staff of alcohol ignition interlock programs. There are up to 52 interlock programs; with nearly one in each state, the District of Columbia, and Puerto Rico. Estimated Number of Respondents: 260 (If 52 administrators and four staff per program were to respond). Estimated Time per Response: The expected average completion time for the questionnaire is 15 minutes, and for the group phone interview it is 60 minutes. Estimate of the Total Annual Reporting and Record Keeping Burden Resulting from the Collection of Information: Participants will incur no burden related to annual reporting or record keeping due to the collection of information. Total Estimated Annual Burden Hours: A total of 273 hours: The estimated burden hours for the questionnaire is 13 hours (52 administrators × .25 hours to take the questionnaire), and the estimated burden hours for the group interviews is 260 hours (260 people × 1 hour). Frequency of Collection: The information collection will be administered a single time. Previous Notice: A 60-day notice in the Federal Register on August 24, 2017 received three comments. The first comment recommended that the questionnaire and the topics of the group interview be provided ahead of time with the managers of each program’s transportation department, to allow managers the opportunity to provide guidance to the staff. NHTSA concurs with this request. The second request was that the information collection should ‘‘not ask for judgments’’ about a department. NHTSA concurs with this request, as the collected information is on features and facts of the programs. The third comment was that ‘‘other approaches to combatting impaired driving’’ warrant support. NHTSA concurs with this comment. VerDate Sep<11>2014 17:07 Jul 16, 2018 Jkt 244001 Comments are Invited: Comments are invited on whether the proposed collection of information is (a) necessary for the Department’s performance; (b) the accuracy of the estimated burden; (c) ways for the Department to enhance the quality, utility and clarity of the information collection; and (d) ways that the burden could be minimized without reducing the quality of the collected information. A comment to OMB is most effective if OMB receives it within 30 days of publication of this notice. Authority: The Paperwork Reduction Act of 1995; 44 U.S.C. Section 3506(c)(2)(A). Issued in Washington, DC, on July 12, 2018. Jeff Michael, Associate Administrator, Research and Program Development. [FR Doc. 2018–15210 Filed 7–16–18; 8:45 am] BILLING CODE 4910–59–P DEPARTMENT OF TRANSPORTATION National Highway Traffic Safety Administration [Docket No. NHTSA–2018–XXXX] Drugs that Impair Safe Driving; Request for Comments National Highway Traffic Safety Administration (NHTSA), Department of Transportation (DOT). ACTION: Request for comment. AGENCY: NHTSA is reviewing the literature on drug use and driving with the aim of updating its Drugs and Human Performance Fact Sheets that are used by the criminal justice community and others as they address drugimpaired driving. The current edition of the Fact Sheets was released in 2004 and included information on the following drugs: Carisoprodol, cocaine, dextromethorphan, diazepam, diphenhydramine, gammahydroxybutyrate (GHB), ketamine, lysergic acid diethylamide (LSD), marijuana, methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), morphine, phencyclidine (PCP), toluene, and zolpidem. NHTSA welcomes comments and suggestions for additional drugs to be considered for inclusion in the new edition of the Fact Sheets as well as relevant research studies that have become available since 2004 that could be included in the updated fact sheets. To the extent possible, such comments and suggestions should be accompanied by information about the drug, including SUMMARY: PO 00000 Frm 00114 Fmt 4703 Sfmt 4703 33305 the extent of its use, its pharmacology and pharmodynamics, and how impairing it is for driving, along with references. Interested parties are invited to submit comments and suggestions on or before September 1, 2018. FOR FURTHER INFORMATION CONTACT: If you have questions about this request for comment, please contact Richard Compton at NHTSAdruginfo@dot.gov or 202–366–2699. Written Comments: Written statements and supporting information submitted during the comment period will be considered. Please submit all written comments no later than September 1, 2018, by any of the following methods: • Federal Rulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting comments. • Mail: Docket Management Facility: U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12–140, Washington, DC 20590–0001. • Hand Delivery or Courier: 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12–140, Washington, DC 20590–0001, between 9 a.m. and 5 p.m. ET, Monday through Friday, except Federal Holidays. • Fax: 202–366–1767. Instructions: All submissions must include the agency name and docket number. Note that all comments received will be posted without change to http://www.regulations.gov, including any personal information provided. Please see the Privacy Act discussion below. Docket: For access to the docket go to http://www.regulations.gov at any time or to 1200 New Jersey Avenue SE, West Building, Ground Floor, Room W12– 140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal Holidays. Telephone: 202–366–9826. Privacy Act: Anyone is able to search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). You may review DOT’s complete Privacy Act Statement in the Federal Register published on April 11, 2000 (Volume 65, Number 70; Pages 19477–78), or you may visit http://www.regulations.gov/ privacy.html. Confidential Business Information: If you wish to submit any information under a claim of confidentiality, you should submit three copies of your DATES: E:\FR\FM\17JYN1.SGM 17JYN1 33306 Federal Register / Vol. 83, No. 137 / Tuesday, July 17, 2018 / Notices complete submission, including the information you claim to be confidential business information, to the Chief Counsel, NHTSA, 1200 New Jersey Ave. SE, W41–326, Washington DC 20590. In addition, you should submit two copies, from which you have deleted the claimed confidential business information, to Docket Management at the address given above. When you send a comment containing information claimed to be confidential business information, you should submit a cover letter setting forth the information specified in our confidential business information regulation (49 CFR part 512). SUPPLEMENTARY INFORMATION: daltland on DSKBBV9HB2PROD with NOTICES Background In the early 2000s, NHTSA convened a panel of international experts on drugimpaired driving to review developments in the field of drugs and human performance and to identify the specific effects that both high priority illicit and prescription drugs have on driving. The experts represented the fields of psychopharmacology, behavioral psychology, drug chemistry, forensic toxicology, medicine, and law enforcement. That effort resulted in the publication of a document entitled Drugs and Human Performance Fact Sheets (DOT HS 809 725) in June 2004. Each Fact Sheet covered one of the selected sixteen drugs that impair driving. The selected drugs included over-the-counter medications such as dextromethorphan and diphenhydramine; prescription medications such as carisoprodol, diazepam, and zolpidem; and abused and/or illegal drugs such as cocaine, GHB, ketamine, LSD, marijuana, methadone, methamphetamine, MDMA, morphine, PCP, and toluene. Each individual drug Fact Sheet covered information regarding drug chemistry, usage and dosage information, pharmacology, drug effects, effects on driving, drug evaluation and classification, and the panel’s assessment of driving risks. More specifically, the Fact Sheets provided details on the physical description of the drug, synonyms, and pharmaceutical or illicit sources; medical and recreational uses, recommended and abused doses, typical routes of administration, and potency and purity; mechanism of drug action and major receptor sites; drug absorption, distribution, metabolism and elimination data; blood and urine concentrations; psychological and physiological effects, and drug interactions; drug effects on VerDate Sep<11>2014 17:07 Jul 16, 2018 Jkt 244001 psychomotor performance effects; driving simulator and epidemiology studies; and drug recognition evaluation profiles. Each Fact Sheet concludes with general statements about the drugs’ ability to impair driving performance. A list of key references and recommended reading was also provided for each drug. Since 2004, new research on these and other impairing drugs has become available. As a result, NHTSA plans to evaluate whether additional drugs that impair driving should be included in the Fact Sheets and to add them as appropriate, as well as to update information on the effects of the sixteen aforementioned drugs on driving. NHTSA will base the revised Fact Sheets on the state of current scientific knowledge. The agency intends to design the revised Fact Sheets to continue to provide practical guidance to toxicologists, pharmacologists, law enforcement officers, attorneys, and the general public to use in the evaluation of future cases. In order to assist on the development of the new edition of the Fact Sheets, NHTSA invites comments and suggestions from the general public on additional drugs as well as relevant research studies that have become available since 2004 that could be included in the updated fact sheets. To the extent possible, such comments and suggestions should be accompanied by information about the drug, including the extent of its use, its pharmacology and pharmodynamics, and how impairing it is for driving, along with references. Authority: 44 U.S.C. Section 3506(c)(2)(A). Issued in Washington, DC, on July 12, 2018. Jeff Michael, Associate Administrator, Research and Program Development. [FR Doc. 2018–15209 Filed 7–16–18; 8:45 am] BILLING CODE 4910–59–P DEPARTMENT OF TRANSPORTATION National Highway Traffic Safety Administration [U.S. DOT Docket No. NHTSA–2018–0060] Reports, Forms, and Record Keeping Requirements National Highway Traffic Safety Administration (NHTSA), DOT. ACTION: Request for public comment on proposed collection of information. AGENCY: Before a Federal agency can collect certain information from the public, it must receive approval from SUMMARY: PO 00000 Frm 00115 Fmt 4703 Sfmt 4703 the Office of Management and Budget (OMB). Under procedures established by the Paperwork Reduction Act of 1995, before seeking OMB approval, Federal agencies must solicit public comment on proposed collections of information, including extensions and reinstatements of previously approved collections. This document describes the collection of information for which NHTSA intends to seek OMB approval. DATES: Comments must be received on or before September 17, 2018. ADDRESSES: You may submit comments identified by DOT Docket Number NHTSA–2018–0060 using any of the following methods: Electronic submissions: Go to http:// www.regulations.gov. Follow the online instructions for submitting comments. Mail: Docket Management Facility, M–30, U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12–140, Washington, DC 20590. Hand Delivery: West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. Fax: 1–202–493–2251. Instructions: Each submission must include the agency name and the docket number for this Notice. Note that all comments received will be posted without change to http:// www.regulations.gov, including any personal information provided. FOR FURTHER INFORMATION CONTACT: Mary Byrd, Contracting Officer’s Representative, Office of Behavioral Safety Research (NPD–320), National Highway Traffic Safety Administration, 1200 New Jersey Avenue SE, Washington, DC 20590. Ms. Byrd’s phone number is 202–366–5595, and her email address is mary.byrd@dot.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995, before an agency submits a proposed collection of information to OMB for approval, it must publish a document in the Federal Register providing a 60-day comment period and otherwise consult with members of the public and affected agencies concerning each proposed collection of information. The OMB has promulgated regulations describing what must be included in such a document. Under OMB’s regulations (5 CFR 1320.8(d)), an agency must ask for public comment on the following: (i) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; E:\FR\FM\17JYN1.SGM 17JYN1

Agencies

[Federal Register Volume 83, Number 137 (Tuesday, July 17, 2018)]
[Notices]
[Pages 33305-33306]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15209]


-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket No. NHTSA-2018-XXXX]


Drugs that Impair Safe Driving; Request for Comments

AGENCY: National Highway Traffic Safety Administration (NHTSA), 
Department of Transportation (DOT).

ACTION: Request for comment.

-----------------------------------------------------------------------

SUMMARY: NHTSA is reviewing the literature on drug use and driving with 
the aim of updating its Drugs and Human Performance Fact Sheets that 
are used by the criminal justice community and others as they address 
drug-impaired driving. The current edition of the Fact Sheets was 
released in 2004 and included information on the following drugs: 
Carisoprodol, cocaine, dextromethorphan, diazepam, diphenhydramine, 
gamma-hydroxybutyrate (GHB), ketamine, lysergic acid diethylamide 
(LSD), marijuana, methadone, methamphetamine, 
methylenedioxymethamphetamine (MDMA), morphine, phencyclidine (PCP), 
toluene, and zolpidem. NHTSA welcomes comments and suggestions for 
additional drugs to be considered for inclusion in the new edition of 
the Fact Sheets as well as relevant research studies that have become 
available since 2004 that could be included in the updated fact sheets. 
To the extent possible, such comments and suggestions should be 
accompanied by information about the drug, including the extent of its 
use, its pharmacology and pharmodynamics, and how impairing it is for 
driving, along with references.

DATES: Interested parties are invited to submit comments and 
suggestions on or before September 1, 2018.

FOR FURTHER INFORMATION CONTACT: If you have questions about this 
request for comment, please contact Richard Compton at 
[email protected] or 202-366-2699.
    Written Comments: Written statements and supporting information 
submitted during the comment period will be considered. Please submit 
all written comments no later than September 1, 2018, by any of the 
following methods:
     Federal Rulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting 
comments.
     Mail: Docket Management Facility: U.S. Department of 
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, 
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery or Courier: 1200 New Jersey Avenue SE, West 
Building Ground Floor, Room W12-140, Washington, DC 20590-0001, between 
9 a.m. and 5 p.m. ET, Monday through Friday, except Federal Holidays.
     Fax: 202-366-1767.
    Instructions: All submissions must include the agency name and 
docket number. Note that all comments received will be posted without 
change to http://www.regulations.gov, including any personal 
information provided. Please see the Privacy Act discussion below.
    Docket: For access to the docket go to http://www.regulations.gov 
at any time or to 1200 New Jersey Avenue SE, West Building, Ground 
Floor, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., 
Monday through Friday, except Federal Holidays. Telephone: 202-366-
9826.
    Privacy Act: Anyone is able to search the electronic form of all 
comments received into any of our dockets by the name of the individual 
submitting the comment (or signing the comment, if submitted on behalf 
of an association, business, labor union, etc.). You may review DOT's 
complete Privacy Act Statement in the Federal Register published on 
April 11, 2000 (Volume 65, Number 70; Pages 19477-78), or you may visit 
http://www.regulations.gov/privacy.html.
    Confidential Business Information: If you wish to submit any 
information under a claim of confidentiality, you should submit three 
copies of your

[[Page 33306]]

complete submission, including the information you claim to be 
confidential business information, to the Chief Counsel, NHTSA, 1200 
New Jersey Ave. SE, W41-326, Washington DC 20590. In addition, you 
should submit two copies, from which you have deleted the claimed 
confidential business information, to Docket Management at the address 
given above. When you send a comment containing information claimed to 
be confidential business information, you should submit a cover letter 
setting forth the information specified in our confidential business 
information regulation (49 CFR part 512).

SUPPLEMENTARY INFORMATION: 

Background

    In the early 2000s, NHTSA convened a panel of international experts 
on drug-impaired driving to review developments in the field of drugs 
and human performance and to identify the specific effects that both 
high priority illicit and prescription drugs have on driving. The 
experts represented the fields of psychopharmacology, behavioral 
psychology, drug chemistry, forensic toxicology, medicine, and law 
enforcement. That effort resulted in the publication of a document 
entitled Drugs and Human Performance Fact Sheets (DOT HS 809 725) in 
June 2004.
    Each Fact Sheet covered one of the selected sixteen drugs that 
impair driving. The selected drugs included over-the-counter 
medications such as dextromethorphan and diphenhydramine; prescription 
medications such as carisoprodol, diazepam, and zolpidem; and abused 
and/or illegal drugs such as cocaine, GHB, ketamine, LSD, marijuana, 
methadone, methamphetamine, MDMA, morphine, PCP, and toluene. Each 
individual drug Fact Sheet covered information regarding drug 
chemistry, usage and dosage information, pharmacology, drug effects, 
effects on driving, drug evaluation and classification, and the panel's 
assessment of driving risks. More specifically, the Fact Sheets 
provided details on the physical description of the drug, synonyms, and 
pharmaceutical or illicit sources; medical and recreational uses, 
recommended and abused doses, typical routes of administration, and 
potency and purity; mechanism of drug action and major receptor sites; 
drug absorption, distribution, metabolism and elimination data; blood 
and urine concentrations; psychological and physiological effects, and 
drug interactions; drug effects on psychomotor performance effects; 
driving simulator and epidemiology studies; and drug recognition 
evaluation profiles. Each Fact Sheet concludes with general statements 
about the drugs' ability to impair driving performance. A list of key 
references and recommended reading was also provided for each drug.
    Since 2004, new research on these and other impairing drugs has 
become available. As a result, NHTSA plans to evaluate whether 
additional drugs that impair driving should be included in the Fact 
Sheets and to add them as appropriate, as well as to update information 
on the effects of the sixteen aforementioned drugs on driving. NHTSA 
will base the revised Fact Sheets on the state of current scientific 
knowledge. The agency intends to design the revised Fact Sheets to 
continue to provide practical guidance to toxicologists, 
pharmacologists, law enforcement officers, attorneys, and the general 
public to use in the evaluation of future cases.
    In order to assist on the development of the new edition of the 
Fact Sheets, NHTSA invites comments and suggestions from the general 
public on additional drugs as well as relevant research studies that 
have become available since 2004 that could be included in the updated 
fact sheets. To the extent possible, such comments and suggestions 
should be accompanied by information about the drug, including the 
extent of its use, its pharmacology and pharmodynamics, and how 
impairing it is for driving, along with references.

    Authority: 44 U.S.C. Section 3506(c)(2)(A).

    Issued in Washington, DC, on July 12, 2018.
Jeff Michael,
Associate Administrator, Research and Program Development.
[FR Doc. 2018-15209 Filed 7-16-18; 8:45 am]
 BILLING CODE 4910-59-P